ALAMEDA,
Calif., May 23, 2024 /PRNewswire/ -- CellFE Inc.,
a cell engineering platform company with a novel microfluidic
technology for non-viral cell therapy manufacturing, announced
today an upcoming presentation by CEO Alla
Zamarayeva, PhD, at the International Society of Gene &
Cell Therapy (ISCT) 2024 Annual Meeting, taking place May 29-June 1, 2024 in Vancouver, BC. The company will also present
an abstract highlighting the use of its non-viral platform in
manufacturing resting T cells with high stemness and superior
viability.
"Current workflows for T-cell manufacturing use fully activated
T-cells via co-stimulation, but the consequent T-cell
differentiation can negatively impact therapeutic outcomes due to
shorter in vivo lifespans and reduced anti-tumor efficacy. Our
technology offers a solution to this manufacturing dilemma by
enabling complex payload delivery to resting T cells while ensuring
high stemness levels post-transfection," said Dr. Zamarayeva. "By
supporting rapid, highly efficient manufacturing workflows for
quiescent cell types, our partners are empowered to create more
potent, durable cell therapies on shorter timescales."
CellFE will be exhibiting at Booth #320 at ISCT 2024 from
May 29 – 31. Attendees are encouraged
to visit the booth for a demo of the Infinity MTxTM
cellular engineering platform or schedule a meeting via the ISCT
partnering portal at https://connect-v3.jujama.com/ISCT-2024.
Sponsor Presentation Details:
Title: A Novel, Microfluidics Approach to Advance Innovative
Cell Therapy Manufacturing, Alla Zamarayeva, PhD
Session Title: Global Showcase
Date and Time: Thursday, May 30,
2024, 6:00 p.m. – 6:15 p.m. PT
Location: Exhibit Hall, Theater A
Poster Presentation Details:
Title: Human Primary Resting T-cell Manufacturing via
Microfluidic Transfection Platform, Ailin
Goff
Session: Poster Networking Reception #1, Gene Editing /
Gene Therapies
Poster Number: 1108
Date and Time: Wednesday, May 29, 2024, 7:00 –
8:30 p.m. PT
Location: Exhibit and Poster Hall
A copy of the sponsor presentation and abstract will be
available at www.cellfebiotech.com after each presentations
concludes.
About CellFE Inc.
CellFE, a cutting-edge microfluidics
company, is transforming the development and manufacturing of
lifesaving cell therapies to make them more accessible to patients.
The Company's microfluidic-based cell engineering platform offers
complex editing with reduced risk of translocation events,
streamlined scalability, and rapid workflows. Benefits of the
CellFE platform include superior cell health and yield with reduced
expansion times, drastically minimizing both vein-to-vein times and
enabling more robust and durable therapies. By limiting the need
for specialized buffers, the technology ensures optimization is
directly transferrable from low to high volumes, so cell therapy
developers can seamlessly scale from research to clinical and
beyond. CellFE is committed to enabling their partners' success
through close collaborations designed to solve the challenges
associated with the development and manufacturing of
next-generation cell therapies.
https://www.cellfebiotech.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cellfe-announces-presentations-at-upcoming-international-society-of-gene--cell-therapy-isct-2024-annual-meeting-302154381.html
SOURCE CellFE